Atherosclerosis Drugs Market to Grow with a CAGR of 2.43% through 2028
Rising prevalence of atherosclerosis and expanding geriatric
population are factors driving the global Atherosclerosis Drugs market in the forecast
period 2024-2028.
According to TechSci Research report, “Atherosclerosis
Drugs Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2028”, the Global Atherosclerosis Drugs Market stood
at USD 18.27 billion in 2022 and is anticipated to grow with a CAGR of 2.43% in
the forecast period, 2024-2028.
Atherosclerosis,
a chronic disease characterized by the accumulation of fatty deposits in the
arteries, remains a significant global health concern. It is a leading cause of
heart attacks, strokes, and other cardiovascular diseases, resulting in
millions of deaths each year. The global atherosclerosis drugs market plays a
crucial role in addressing this health issue, and its growth and dynamics are
influenced by several market drivers. One of the primary market drivers for
atherosclerosis drugs is the increasing prevalence of the disease. Sedentary
lifestyles, poor dietary habits, and a rise in risk factors such as obesity,
diabetes, and hypertension have contributed to the growing incidence of
atherosclerosis. As more people are diagnosed with this condition, there is a
greater demand for effective treatments, driving the market for atherosclerosis
drugs.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Atherosclerosis Drugs Market.”
The global demographic shift toward an
aging population is another crucial driver of the atherosclerosis drugs market.
Atherosclerosis is more common in older individuals, and as the elderly
population grows, so does the pool of potential patients. This demographic
trend creates a sustained demand for drugs that can manage atherosclerosis and
its associated complications. Advancements in pharmaceutical research and
development have led to the discovery of innovative drugs and therapies for
atherosclerosis. These new treatments target various aspects of the disease,
such as reducing cholesterol levels, managing blood pressure, and addressing
inflammation. Technological progress in drug development has expanded the
therapeutic options available to healthcare providers, offering better outcomes
for patients and driving market growth.
Efforts to raise awareness about
cardiovascular diseases, including atherosclerosis, have resulted in more
individuals seeking regular check-ups and screenings. Early detection of
atherosclerosis enables prompt intervention, often involving the use of
pharmaceuticals. As public awareness grows, there is a corresponding increase
in the demand for atherosclerosis drugs. Health-conscious individuals are
increasingly adopting lifestyle modifications to prevent or manage
atherosclerosis. These changes include healthier diets, regular exercise, and
smoking cessation. While lifestyle modifications are essential for disease prevention,
they are often complemented by pharmaceutical interventions. The market for
atherosclerosis drugs benefits from individuals proactively addressing their
risk factors.
The Global Atherosclerosis Drugs Market is segmented into
diagnosis, treatment, route of administration, end user and company.
Based on end user, the hospitals segment has emerged as the
predominant market leader. Hospitals and
clinics are undeniably the key players dominating the global atherosclerosis
drugs market. Their role in diagnosing, treating, and managing atherosclerosis
is pivotal in addressing the growing burden of this disease worldwide. With
continued advancements in drug development and healthcare delivery, hospitals
and clinics will remain at the forefront of the fight against atherosclerosis,
improving the quality of life for countless patients.
Based on region, North America segment is expected to
grow during the forecast period. North America boasts a robust
regulatory framework for drug approval and safety. The U.S. Food and Drug Administration
(FDA) and Health Canada maintain rigorous standards for drug testing and
approval, ensuring that atherosclerosis drugs meet high-quality and safety
criteria. This regulatory rigor bolsters confidence in North American
pharmaceutical products, attracting investments and partnerships from across
the world. Advancements in
healthcare technology, including diagnostic tools, imaging techniques, and drug
delivery systems, have significantly contributed to North America's dominance
in the atherosclerosis drugs market. These innovations enable early disease
detection, personalized treatment plans, and targeted drug delivery, improving
patient outcomes and fueling market growth.
The Asia Pacific region is experiencing rapid market
growth. The region has consistently high healthcare expenditure per capita,
with governments and private institutions investing significantly in healthcare
services and medications. The willingness to allocate resources to healthcare
needs, including atherosclerosis treatment, has created a conducive environment
for pharmaceutical companies to thrive.
Major companies operating in Global Atherosclerosis
Drugs Market are:
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co
- Allergan Plc
- AstraZeneca
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global atherosclerosis drugs market is driven by
a combination of factors, including the rising prevalence of the disease, an
aging population, technological advancements in drug development, increased
awareness and screening, lifestyle modifications, government initiatives, and
growing healthcare expenditure. These drivers collectively contribute to the
market's growth and underscore the importance of continued research and
development in the field of atherosclerosis treatment.,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Atherosclerosis Drugs Market By Diagnosis
(Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram,
Blood Tests, Others), By Treatment (Medication, Surgery, Others), By Route of
Administration (Oral, Parenteral, Others),By End User (Hospitals & Clinics,
Ambulatory Care Centers, Others), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Atherosclerosis Drugs Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Atherosclerosis Drugs Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com